Navigation Links
Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant
Date:7/20/2011

CLEVELAND, July 20, 2011 /PRNewswire/ -- One of Frantz Medical Group's (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today announced that it has been awarded an Ohio Third Frontier grant to further develop and commercialize a novel electromagnetic guidewire system for penetrating through vascular Chronic Total Occlusions (CTOs), in lieu of invasive open heart surgery such as Coronary Artery Bypass Graft (CABG).  

VasoStar's primary clinical development partner is the Cleveland Clinic's Lerner Research Institute.  The VasoStar advisory team consists of world renowned cardiovascular clinicians including Dr. Patrick Whitlow, Director of Interventional Cardiology, Cleveland Clinic; Dr. Kiyo Fukamachi, Director of the Cardiovascular Dynamics Laboratory, Lerner Research Institute, Cleveland Clinic; Dr. Marc Penn, Director of Research, Summa Cardiovascular Institute; and Dr. Peter Fitzgerald, Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL),  Stanford University Medical School. VasoStar has also received grant support and technical and commercial counsel from the Global Cardiovascular Innovation Center (GCIC), an Ohio based product commercialization consortium led by the Cleveland Clinic.

This $1,000,000 grant, in addition to FMG's financial and engineering support, will allow VasoStar to complete development of and collect additional safety data for the guidewire and catheter system in preparation for FDA and CE regulatory submissions.  The VasoStar technology has been demonstrated to be safe in an animal study performed at the Lerner Research Institute.  A number of preeminent interventional cardiologists have provided positive feedback regarding the VasoStar system's usability and potential effectiveness following hands-on experience with prototype devices in arterial pathway models with simulated blockages.  With the assistance of the Ohio Third Frontier grant, VasoStar will develop the first guidewire system that offers the clinician on-demand CTO-crossing assistance from the guidewire's embedded miniaturized electromagnetic engines.  Product launch is targeted for 2013.

"We are delighted and grateful to have the support of the State of Ohio," said Stephanie Harrington, Chief Operating Officer of VasoStar.  "The Ohio Third Frontier grant will allow us to further the development of an effective solution to crossing CTOs with a guidewire which will improve patient outcome without altering the clinician's guidewire technique. In addition, this grant offers VasoStar the ability to build and expand Northeast Ohio's cardiovascular medical device engineering and manufacturing competency in partnership with the Cleveland Clinic and Interplex Medical."

About VasoStar Inc.

VasoStar Inc. was established to develop and commercialize a solution to the unmet need for a CTO crossing percutaneously: a miniaturized electromagnetic solenoid that produces longitudinal vibration at the guidewire tip for safely penetrating CTOs without significantly changing the clinician's guidewire technique and feel. VasoStar has exclusively licensed this technology from EYoCa Medical Ltd., an Israeli company founded by three Israeli scientists, including VasoStar's Chief Technology Officer, Mr. Ran Carmeli, and two leading U.S. interventional cardiovascular clinicians and researchers, the late Dr. Donald Baim, Chief Scientific and Medical Officer, Boston Scientific (previously Professor, Harvard Medical School) and Professor Peter Fitzgerald, Stanford University School of Medicine. Frantz Medical Group (www.FrantzGroup.com), established in 1979, is an Ohio-based consortium of companies specializing in the development and manufacturing of medical devices and diagnostics. FMG has majority ownership of VasoStar Inc. and has incubated VasoStar's initial development efforts.

About Ohio Third Frontier

The Ohio Third Frontier targets its investments to support technology areas that represent Ohio's key competitive opportunities. The Ohio Third Frontier was created in 2002 and is an unprecedented commitment to create new technology-based products, companies, industries and jobs. Their programs accelerate the growth and development of the biomedical, medical imaging, and sensors industries and their supply chains in Ohio.


'/>"/>
SOURCE Frantz Medical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
2. Frantz Medical Group Announces the Promotion of Stephanie Harrington to Chief Operating Officer
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... BURLINGAME, Calif. , April 28, 2016 /PRNewswire/ ... first-ever widely accessible breast and ovarian cancer risk ... cancer panel analyzing 30 genes that highly impact ... and women. Available today, the Color Test analyzes ... pancreatic, prostate, stomach, and uterine cancers. The Color ...
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... ... 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) 2nd ... sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, walkers ... and Walk and 1-mile walk were held to increase awareness about Lyme disease ...
(Date:4/29/2016)... PA (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the ... Prize, the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... , ... April 29, 2016 , ... For those who ... the meal to miss. That was among the many new lifestyle diet tips offered ... recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that ...
Breaking Medicine News(10 mins):